Literature DB >> 24574759

Primary effusion lymphoma-like lymphoma in a patient with inflammatory bowel disease.

Elchanan Nussinson1, Fahmi Shibli1, Azmi Shahbari1, Wasseem Rock1, Mazen Elias1, Irit Elmalah1.   

Abstract

A 77-year-old man with inflammatory bowel disease (IBD) and who was treated with anti-tumor necrosis factor (TNF), 6-mercaptopurine and corticosteroids, presented with primary effusion lymphoma-like lymphoma (PEL-like lymphoma) with massive ascites. The patient's clinical course was complicated by acute renal insufficiency and hypotension, which led to death within 2 wk. In general, patients with IBD may have an increased risk for development of lymphoma, which is frequently associated with immunosuppressive and/or anti-TNF antibody therapies. PEL is a rare subset of lymphoma localized to serous body cavities, lacks tumor mass or nodal involvement, and is associated with infection by human herpes virus 8 (HHV-8). Primary neoplastic effusion may also be present in patients with large B-cell lymphoma without evidence of human immunodeficiency virus or HHV-8 infections. This type of lymphoma is classified as PEL-like lymphoma. Both PEL and PEL-like lymphoma types have been reported in patients undergoing immunosuppressive therapy, but to the best of our knowledge, the case described herein represents the first PEL-like lymphoma occurring in a patient with IBD.

Entities:  

Keywords:  Immunosuppressive therapy; Inflammatory bowel disease; Lymphoma; Primary effusion lymphoma; Primary effusion lymphoma-like lymphoma

Mesh:

Substances:

Year:  2014        PMID: 24574759      PMCID: PMC3921495          DOI: 10.3748/wjg.v20.i3.857

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  52 in total

Review 1.  Review article: does the use of immunosuppressive therapy in inflammatory bowel disease increase the risk of developing lymphoma?

Authors:  J R Bebb; R P Logan
Journal:  Aliment Pharmacol Ther       Date:  2001-12       Impact factor: 8.171

Review 2.  Herpes virus type 8-negative primary effusion lymphoma associated with PAX-5 gene rearrangement and hepatitis C virus: a case report and review of the literature.

Authors:  R Ichinohasama; I Miura; N Kobayashi; Y Saitoh; J F DeCoteau; Y Saiki; S Mori; M E Kadin; K Ooya
Journal:  Am J Surg Pathol       Date:  1998-12       Impact factor: 6.394

3.  Primary intestinal lymphoma in patients with inflammatory bowel disease: a descriptive series from the prebiologic therapy era.

Authors:  Stefan D Holubar; Eric J Dozois; Edward V Loftus; Swee H Teh; Luis A Benavente; W Scott Harmsen; Bruce G Wolff; Robert R Cima; David W Larson
Journal:  Inflamm Bowel Dis       Date:  2010-11-04       Impact factor: 5.325

4.  Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine.

Authors:  A Kandiel; A G Fraser; B I Korelitz; C Brensinger; J D Lewis
Journal:  Gut       Date:  2005-08       Impact factor: 23.059

5.  Prognosis of lymphoma in patients following treatment with 6-mercaptopurine/azathioprine for inflammatory bowel disease.

Authors:  Keith Sultan; Burton I Korelitz; Daniel Present; Seymour Katz; Suzanne Sunday; Iuliana Shapira
Journal:  Inflamm Bowel Dis       Date:  2012-01-12       Impact factor: 5.325

6.  Epstein-Barr virus-positive lymphoma in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine.

Authors:  Gerald A Dayharsh; Edward V Loftus; William J Sandborn; William J Tremaine; Alan R Zinsmeister; Thomas E Witzig; William R Macon; Lawrence J Burgart
Journal:  Gastroenterology       Date:  2002-01       Impact factor: 22.682

7.  Primary effusion lymphoma in two HIV-negative patients successfully treated with pleurodesis as first-line therapy.

Authors:  X Yiakoumis; G A Pangalis; M-C Kyrtsonis; T P Vassilakopoulos; F N Kontopidou; C Kalpadakis; P Korkolopoulou; G Levidou; A Androulaki; M P Siakantaris; S Sachanas; A Andreopoulos
Journal:  Anticancer Res       Date:  2010-01       Impact factor: 2.480

8.  Inflammatory bowel disease is not associated with an increased risk of lymphoma.

Authors:  J D Lewis; W B Bilker; C Brensinger; J J Deren; D J Vaughn; B L Strom
Journal:  Gastroenterology       Date:  2001-11       Impact factor: 22.682

Review 9.  KSHV/HHV8-negative effusion-based lymphoma, a distinct entity associated with fluid overload states.

Authors:  Serge Alexanian; Jonathan Said; Mark Lones; Sheeja T Pullarkat
Journal:  Am J Surg Pathol       Date:  2013-02       Impact factor: 6.394

Review 10.  HIV and HHV-8 negative primary effusion lymphoma in a patient with hepatitis C virus-related liver cirrhosis.

Authors:  Gladell P Paner; Joanne Jensen; Kimberly E Foreman; Cesar V Reyes
Journal:  Leuk Lymphoma       Date:  2003-10
View more
  3 in total

Review 1.  Human herpesvirus 8-negative effusion-based large B-cell lymphoma: a distinct entity with unique clinicopathologic characteristics.

Authors:  Savanah D Gisriel; Ji Yuan; Ryan C Braunberger; Danielle L V Maracaja; Xueyan Chen; Xiaojun Wu; Jenna McCracken; Mingyi Chen; Yi Xie; Laura E Brown; Peng Li; Yi Zhou; Tarsheen Sethi; Austin McHenry; Ronald G Hauser; Nathan Paulson; Haiming Tang; Eric D Hsi; Endi Wang; Qian-Yun Zhang; Ken H Young; Mina L Xu; Zenggang Pan
Journal:  Mod Pathol       Date:  2022-05-13       Impact factor: 8.209

2.  Primary human herpesvirus 8-negative effusion-based lymphoma: a large B-cell lymphoma with favorable prognosis.

Authors:  Daisuke Kaji; Yasunori Ota; Yasuharu Sato; Koji Nagafuji; Yasunori Ueda; Masataka Okamoto; Yasushi Terasaki; Naoko Tsuyama; Kosei Matsue; Tomohiro Kinoshita; Go Yamamoto; Shuichi Taniguchi; Shigeru Chiba; Koichi Ohshima; Koji Izutsu
Journal:  Blood Adv       Date:  2020-09-22

3.  Spontaneous regression of dasatinib-related primary effusion lymphoma-like lymphoma.

Authors:  Kenta Hayashino; Yusuke Meguri; Ryouya Yukawa; Aya Komura; Makoto Nakamura; Chikamasa Yoshida; Kazuhiko Yamamoto; Wakako Oda; Kenji Imajo
Journal:  Int J Hematol       Date:  2022-09-06       Impact factor: 2.319

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.